Skip to main content
Fig. 7 | Cancer Cell International

Fig. 7

From: The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1α/VEGF signaling pathway

Fig. 7

Blocking VEGF impairs THCA cells’ movement, migration and invasion abilities. AB BCPAP/Axitinib and BHT101/Axitinib cells were less motile at 24 h compared with BCPAP/parental and BCPAP/ctrl, and BHT101/parental and BHT101/ctrl cells. CD Wound size of BCPAP/Axitinib and BHT101/Axitinib, BCPAP/parental and BCPAP/ctrl, and BHT101/parental and BHT101/ctrl cells (*P < 0.05). EF BCPAP/ Axitinib and BHT101/Axitinib cells exhibited reduced movement through Matrigel than BCPAP/parental and BCPAP/ctrl, and BHT101/parental and BHT101/ctrl cells. GH Cell number in every field in BCPAP/Axitinib and BHT101/Axitinib, BCPAP/parental and BCPAP/ctrl, and BHT101/parental and BHT101/ctrl cells (*P < 0.05, **P < 0.01)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us